



3475 Edison Way, Ste. R, Menlo Park, CA 94025 tel (650) 995-7508

NewGen Granted Patent for NT-113 in Europe

MENLO PARK, CA (May 23, 2018) -- NewGen Therapeutics, Inc. (NewGen), a late pre-clinical stage company focused on the development of novel targeted therapeutics for the treatment of cancer today announced the European Patent Office (EPO) has issued a "Notice of Intention to Grant" for NewGen's patent application covering the company's lead product candidate, NT-113. The patent will provide NewGen's NT-113 with broad composition of matter patent protection, further strengthening the company's patent portfolio.

NT-113 is a potent orally administered pan-erbB inhibitor with high penetration into the brain being developed for patients with solid tumors including non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC) and other solid tumors that have one or more mutated erbB receptors and have metastasized to the brain.

About NewGen

NewGen Therapeutics is a privately held pharmaceutical company developing patient-targeted cancer drugs that are designed to overcome limitations of currently available therapies. The company's pipeline includes multiple programs with novel small molecule drug leads against clinically important targets, each addressed to significant medical needs. NT-113, a potent irreversible pan-erbB inhibitor with high brain penetration, is the company's most advanced program and has demonstrated anti-cancer activity in multiple intracranial patient derived xenograft (PDX) mouse models.

NewGen's strategy is to discover and develop novel targeted anti-cancer agents and partner with pharmaceutical companies for clinical development and commercialization. For more information, please visit our website at <http://www.newgenther.com>.

For Further Information Contact:

Harry Pedersen
NewGen Therapeutics
+1.650.995.7508 ext. 101